| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;107:2771.)
© 2003 American Heart Association, Inc.
Clinician Update |
From the University of Michigan, Ann Arbor.
Correspondence to Kim A. Eagle, MD, Division of Cardiology, University of Michigan Health System, 3910 Taubman Center, 1500 E Medical Center Dr, Ann Arbor, MI 48103. E-mail keagle{at}umich.edu
| Introduction |
|---|
|
|
|---|
| Eight Steps to the Optimal Perioperative Outcome |
|---|
|
|
|---|
(1) Assess the Patients Clinical Features
The history and physical examination should emphasize identification of markers of cardiac risk and assess the patients cardiac status. High-risk cardiac conditions include recent myocardial infarction (MI), decompensated heart failure (HF), unstable angina, symptomatic arrhythmias, and symptomatic valvular heart disease. The patients underlying cardiac conditions, although apparently stable at present, may become manifest during perioperative stresses. Such conditions include stable angina, distant MI, prior HF, or moderate valvular disease. One should also identify serious comorbid conditions such as diabetes, stroke, renal insufficiency, and pulmonary disease because these illnesses may also affect periprocedural outcomes. Table 1 lists the factors that increase the risk of perioperative cardiac complications in patients undergoing noncardiac surgery.2
|
|
(2) Evaluate Functional Status
The history should assess functional capacity (the ability to climb stairs, do ones own housework, perform regular exercise, etc). Patients who are able to exercise on a regular basis without limitations generally have sufficient cardiovascular reserve to withstand very stressful operations. Conversely, those with limited exercise capacity may have poor cardiovascular reserve, which may become manifest after noncardiac surgery. Poor functional status is associated with a worse short- and long-term outcome in patients undergoing noncardiac surgery.
(3) Consider the Patients Surgery-Specific Risk
The type of surgery has important implications for perioperative risk. Table 2 categorizes surgery-specific risk into high-, intermediate-, and low-risk categories. Emergency surgery, particularly in the elderly, is associated with a high risk. Patients undergoing vascular surgery constitute another high-risk group, in part because of concomitant coronary artery disease. Fleisher et al3 demonstrated that aortic and infrainguinal surgery are each associated with high 30-day and 1-year mortality. Extensive surgical procedures, particularly those in the abdomen or thorax and those associated with large volume shifts and/or blood loss, are considered to be higher risk.
(4) Decide if Further Noninvasive Evaluation Is Needed
Consideration of steps 1, 2, and 3 helps the clinician determine if further noninvasive evaluation is likely to be helpful. Patient who are at low risk based on clinical features, functional status, and proposed low-risk surgery do not generally require any further evaluation. In contrast, patients who are deemed high-risk based on clinical features, have poor functional status, and are being considered for high-risk surgery may benefit from further evaluation. On the basis of the prior steps, intermediate risk patients may be empirically treated with ß-blocker therapy or may undergo noninvasive testing. Individuals with more than 3 clinical risk factors and extensive myocardial ischemia on preoperative stress imaging testing appear to have a high complication rate even with effective ß-blocker therapy and should be considered for invasive evaluation and coronary revascularization (Figure).4 In general, noninvasive testing is most useful in intermediate risk patients.
|
(5) Decide When to Recommend Invasive Evaluation
In patients with unstable angina or evidence of residual ischemia after recent MI, coronary angiography is often indicated. In general, indications for preoperative coronary angiography are similar to those identified for the nonoperative setting and include evidence of high risk based on noninvasive testing, angina unresponsive to adequate medical therapy, unstable angina, and proposed intermediate-risk or high-risk noncardiac surgery after equivocal noninvasive test results. This stepwise approach to preoperative assessment allows judicious use of both noninvasive and invasive procedures while preserving a low rate of cardiac complications.5
Coronary stents are now used in more than 80% of percutaneous coronary interventions (PCIs). Use of stents during PCI immediately before noncardiac surgery presents a unique challenge because of the risk of stent thrombosis and perioperative bleeding during the initial post-surgical period.6 Serious bleeding may result from dual antiplatelet therapy, which is routine after PCI stenting. Coronary thrombosis may occur in those who do not receive 4 full weeks of dual antiplatelet therapy after stenting.6 The American College of Cardiology/American Heart Association guideline recommends that surgeons wait at least 2 weeks, preferably 4 weeks, after coronary stenting to perform noncardiac surgery to allow complete endothelization and a full course of antiplatelet therapy to be given. Post-stenting therapy currently includes a combination of aspirin and clopidogrel for at least 4 weeks, followed by aspirin for an indefinite period.
(6) Optimize Medical Therapy
Patients should be receiving optimal medical therapy, both perioperatively and long-term, based on their underlying cardiac condition. Individuals with angina should receive aspirin, ß-blockers, and nitrates, and if there is evidence of ischemia despite ß-blockers, calcium channel blockers should be considered. Individuals who have had a prior MI should generally be taking aspirin, ß-blockers, and frequently a statin. For those with HF, an angiotensin-converting enzyme inhibitor or an angiotensin-receptor blocker should be used when the left ventricular ejection fraction is less than 40%. Such patients should also be taking ß-blockers. In hypertensive individuals, ß-blockers before surgery may be particularly effective. In individuals with diabetes, optimizing blood pressure control with angiotensin-receptor blockers and a ß-blocker represents a desirable combination. Table 1 lists the independent clinical predictors of perioperative cardiac complications and the potential role of ß-blockers in each circumstance. Patients with symptomatic aortic or mitral stenosis should preferably have the valve treated definitively before elective noncardiac surgery. Individuals with valvular regurgitation should generally receive vasodilator therapy to decrease afterload and reduce regurgitant volume. Current smokers should be strongly counseled to stop before surgery to reduce potential cardiac and pulmonary complications.
For the high-risk coronary patient, the ß-blocker dose should be titrated to achieve a target heart of 60 beats per minute or less, anemia should be promptly identified and corrected, and postoperative pain should be well controlled with adequate doses of analgesics to reduce catecholamine levels. These individuals should generally also continue taking aspirin, a statin, and, when indicated, an angiotensin-converting enzyme inhibitor. Inotropic agents, which increase myocardial oxygen demand, should be avoided whenever possible.
(7) Perform Appropriate Perioperative Surveillance
In patients with known or suspected coronary artery disease, ECGs should be obtained at baseline, immediately after surgery, and on the first 2 days after surgery.7 Biomarkers such as creatine kinase-MB and troponin should be measured in high-risk patients after surgery and on the following day. The possibility of perioperative ischemia or MI can then be estimated on the basis of the magnitude of biomarker elevation, new ECG abnormalities, hemodynamic instability, and quality and intensity of chest pain or other symptoms. Antiplatelet agents should be reinstituted postoperatively as soon as feasible to reduce cardiovascular risk. Patients who develop ST-elevation MI should be considered for urgent angiography and coronary reperfusion, whereas patients with nonST-elevation MI should undergo risk stratification after initial stabilization with intensive medical therapy. Individuals who develop HF after surgery should be evaluated for the pathophysiology of HF and treated on the basis of the precipitating or underlying cause.
(8) Design Maximal Long-Term Therapy
The evaluation before and after noncardiac surgery should be used as an opportunity for assessment and management of modifiable risk factors for coronary artery disease, heart failure, hypertension, stroke, and other cardiovascular diseases. Assessment for hypercholesterolemia, smoking, hypertension, diabetes, physical inactivity, peripheral vascular disease, cardiac murmurs, arrhythmias, conduction abnormalities, and/or perioperative ischemia may lead to evaluation and treatments that reduce future cardiovascular risk. Patients who experience repetitive postoperative myocardial ischemia and/or sustain a perioperative MI are at substantially elevated long-term cardiac risk and should be a particular focus for risk factor interventions and risk stratification with noninvasive testing and/or coronary angiography. Patients should be instructed on the benefits of regular exercise and complete smoking cessation and should receive optimal medical therapy for identified cardiac conditions in the form of antiplatelet therapy, ß-blockers, angiotensin-converting enzyme inhibitors, and lipid lowering therapy when appropriate.
Case: Clinical Results and Conclusions
This patient was at elevated cardiac risk based on his clinical features, limited functional status, and planned high-risk vascular surgery. He underwent a dobutamine-stress echocardiogram that revealed extensive anterolateral ischemia. Coronary angiography revealed 90% stenosis in the proximal portion of the left anterior descending artery. He underwent successful coronary stenting and began taking metoprolol, ramipril, and clopidogrel in addition to his existing regimen of aspirin, nitrates, glyburide, and lovastatin. Clopidogrel was administered for 4 weeks, and the patient underwent elective vascular surgery 1 week after stopping clopidogrel. His postoperative course was uneventful, with no evidence of myocardial ischemia, and he was discharged on the fourth post-operative day.
| Conclusion |
|---|
|
|
|---|
Ironically, many patients presenting for noncardiac surgery have not had a meticulous cardiovascular evaluation recently (or ever!). Furthermore, many such patients will undergo a procedure that creates a sustained cardiovascular stress quite beyond what they may experience in daily life. Therefore, the cardiovascular consultant must identify underlying conditions and evaluate and treat them using cost-effective and evidence-based guidelines, thereby benefiting patients both for the short-term and long-term.9
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
A. Auerbach and L. Goldman Assessing and Reducing the Cardiac Risk of Noncardiac Surgery Circulation, March 14, 2006; 113(10): 1361 - 1376. [Full Text] [PDF] |
||||
![]() |
H.-J. Priebe Perioperative myocardial infarction--aetiology and prevention Br. J. Anaesth., July 1, 2005; 95(1): 3 - 19. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Mukherjee and K. A. Eagle Ischemia, revascularization, and perioperative troponin elevation after vascular surgery J. Am. Coll. Cardiol., August 4, 2004; 44(3): 576 - 578. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |